The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics, Inc. ...

Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. on behalf of investors who purchased its common stock during the February 8, 2024 IPO, with a lead plaintiff deadline set for February 7, 2025 [1]. Group 1: Allegations Against Kyverna - The lawsuit alleges that Kyverna's prospectus and registration statements contained materially false and misleading statements regarding the company's business, operations, and prospects [2]. - Specifically, it is claimed that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors in Kyverna have until February 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will act on behalf of all class members and typically is the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions of dollars for victims of fraud and corporate misconduct [5]. - The firm encourages Kyverna investors who have suffered significant losses to contact them for more information [4].

Core Viewpoint - Kyverna Therapeutics, Inc. (KYTX) is facing a class action lawsuit, which has been notified to its shareholders by Levi & Korsinsky, indicating potential legal challenges for the company [1] Group 1 - The class action lawsuit is related to allegations against Kyverna Therapeutics, which may impact the company's reputation and financial standing [1] - Shareholders are urged to be aware of an upcoming deadline concerning the lawsuit, emphasizing the importance of timely action [1] - The notification serves as a reminder for investors to stay informed about legal proceedings that could affect their investments in Kyverna Therapeutics [1]

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics ...

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Kyverna Therapeutics, Inc. to Contact the Firm Today! ...

Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX ...

NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna’s initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Group 1 - The article announces a deadline for joining a class action lawsuit against Kyverna Therapeutics, Inc. (KYTX) [1] - The deadline to join the class action is set for February 7, 2025 [1] - The lawsuit pertains to potential grievances related to Kyverna Therapeutics, Inc. [1]

Core Viewpoint - Kyverna Therapeutics, Inc. is facing a lawsuit for alleged violations of securities laws, which may impact investors and their interests [1] Group 1 - The lawsuit is being pursued by the Schall Law Firm, indicating potential legal ramifications for the company [1] - Investors affected by the alleged violations are encouraged to reach out to the law firm for assistance [1]

Group 1 - The article discusses a class action lawsuit involving Kyverna Therapeutics, Inc. and highlights the opportunity for shareholders to take action [1] - The law firm Bronstein, Gewirtz and Grossman, LLC is mentioned as the contact for shareholders interested in participating in the lawsuit [1] - The focus is on the potential implications for shareholders and the legal proceedings surrounding the company [1]